Advances in the Treatment of Metastatic Breast Cancer
Hormone receptor positive/HER2 negative metastatic breast cancer presents many therapeutic decision-making challenges. In this CME activity, you will find answers to the most important clinical questions posed by oncologists attending a series of live Tumor Board meetings, held across the country in mid-2016.
• Register or login and click the Start button
• Complete course evaluation
• Download Certificate
This activity was developed for hospital-based oncologists, community oncologists, oncology fellows and other health care professionals who have an interest in managing patients with metastatic breast cancer.
At the conclusion of this activity, participants should be better able to:
- Explain the mechanism of action for CDK4/6 inhibitors
- Interpret the clinical implications of recent clinical data and ongoing trials involving the CDK4/6 inhibitors in metastatic breast cancer
- Devise treatment plans for metastatic breast cancer patients that include the appropriate use of CDK4/6 inhibitors
- Evaluate the safety and toxicity profiles of CDK4/6 inhibitors